Week of January 23, 2017

- NIH Implementation of the Interim-RPPR while a Renewal Application is Under Consideration (NOT-OD-17-037)
  National Institutes of Health

- Notice of the Publication of the Final Rule on the Federal Policy for the Protections of Human Subjects (Common Rule) (NOT-OD-17-038)
  National Institutes of Health

- Registration Open for the Spring 2017 NIH Regional Seminar on Program Funding & Grants Administration - New Orleans, Louisiana (NOT-OD-17-039)
  National Institutes of Health

- Clarification of Number of Health Care System Partners Required for RFA-RM-16-019 NIH Health Care Systems Research Collaboratory - Demonstration Projects for Pragmatic Clinical Trials (UG3/UH3) (NOT-RM-17-007)
  NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination

- Notice Announcing Availability of Common Data Elements for Tobacco Regulatory Research via the PhenX Toolkit (NOT-OD-17-034)
  National Institutes of Health

- Reminder: New Appendix policy for NIH/AHRQ/NIOSH Applications submitted for Due Dates On or After January 25, 2017 (NOT-OD-17-035)
  National Institutes of Health

- Notice of Correction to Key Dates in RFA-CA-17-015 "Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)" (NOT-CA-17-013)
  National Cancer Institute

- Notice of Correction to Key Dates in RFA-CA-17-016 "Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)" (NOT-CA-17-014)
  National Cancer Institute

- Notice of Correction to Key Dates in RFA-CA-17-001 "Canine Immunotherapy Trials and Correlative Studies (U01)" (NOT-CA-17-015)
  National Cancer Institute

- Notice of Correction to Key Dates in RFA-CA-17-002 "Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)" (NOT-CA-17-016)
  National Cancer Institute

- Notice of Change of Application Due Date to RFA-CA-16-501 "Limited Competition: Cancer Immunotherapy Trials Network (CITN)(UM1)" (NOT-CA-17-017)
  National Cancer Institute

- NIH & AHRQ Update Font Guidelines for Applications to Due Dates On or After January 25, 2017 (NOT-OD-17-030)
  National Institutes of Health

- Notice of Availability of Frequently Asked Questions and a Recording of the Pre-application Webinar on the NIH Illuminating the Druggable Genome (IDG) Program Website for RFA-RM-16-024, RFA-RM-16-025, and RFA-RM-16-026 (NOT-RM-17-006)
  NIH Roadmap Initiatives

- Change to Standard Due Dates for Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowships to Promote Diversity in Health Related Research (F31 - Diversity) (NOT-OD-17-029)
  National Institutes of Health

- Notice of Correction to PAR-17-093 "Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)" (NOT-CA-17-012)
  National Cancer Institute

- New Salary Allowance for NIDA Mentored Clinical Scientists Development Program Award (K12) Scholars (NOT-DA-17-007)
  National Institute on Drug Abuse
- Notice of Removal of Eligibility of NIDDK Funded High Impact Research Infrastructure - Cooperative Agreement Awards (UC4) for PA-16-288 "Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)" *(NOT-DK-17-007)*
  National Institute of Diabetes and Digestive and Kidney Diseases
- Notice of Updates to the IMAG Multiscale Modeling Initiative (PAR-15-085) *(NOT-EB-16-011)*
  National Institute of Biomedical Imaging and Bioengineering, Department of Energy, Food and Drug Administration, The Foundation for the National Institutes of Health, National Aeronautics and Space Administration, National Center for Complementary and Integrative Health, National Cancer Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Science Foundation, Office of Behavioral and Social Science Research, Office of Naval Research
- Notice of Change to Application Due Date for RFA-EB-17-001 "BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01)" *(NOT-EB-16-013)*
  National Institute of Biomedical Imaging and Bioengineering
- Notice of Change to Application Due Date for RFA-EB-17-002 "BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01)" *(NOT-EB-16-014)*
  National Institute of Biomedical Imaging and Bioengineering
- Notice of the Cancellation of the Biomedical/Biobehavioral Research Administration Development (BRAD) Award Program *(NOT-HD-16-040)*
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
- Notice of Change in Data Table Instructions in RFA-HD-18-011 "Child Health Research Career Development Award (CHRCDA) Program (K12)" *(NOT-HD-16-041)*
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
- Notice of Extension of the Response Date for NOT-LM-17-002 "Strategic Plan for the National Library of Medicine, National Institutes of Health" *(NOT-LM-17-003)*
  National Library of Medicine
- Notice of Intent to Publish a Funding Opportunity Announcement for NIMHD Specialized Centers of Excellence for Research on Minority Health and Health Disparities (U54) *(NOT-MD-17-001)*
  National Institute on Minority Health and Health Disparities
- Ruth L. Kirschstein National Research Service Awards (NRSA) Postdoctoral Stipends, Training Related Expenses, Institutional Allowance and Tuition/Fees Effective for Fiscal Year 2017 *(NOT-OD-17-003)*
  National Institutes of Health
- Revised SF424 (R&R) Application Guides and Supplemental Instructions Available *(NOT-OD-17-023)*
  National Institutes of Health
- New to the NIH Grants Process? NIH Announces 2017 NIH Regional Seminar Locations in New Orleans, LA and Baltimore, MD *(NOT-OD-17-026)*
  National Institutes of Health
  National Institutes of Health
- Notice on Award Administration Information for the NCI Outstanding Investigator Award (R35) *(NOT-CA-17-006)*
  National Cancer Institute
- Notice of Change to Award Project Period RFA-DA-17-024 "Optimizing the HIV Care Continuum for Substance Abusing Populations at High-Risk and/or Living with HIV (R01)" *(NOT-DA-17-006)*
  National Institute on Drug Abuse
- Notice of Revision to NIDDK-specific Policies Related to New Salary and Research Cost Allowances for K08 and K23 Career Development Awards *(NOT-DK-17-003)*
  National Institute of Diabetes and Digestive and Kidney Diseases
- Notice of NIDDK’s Withdrawal from Participation in PA-16-206 "Midcareer Investigator Award in Patient-Oriented Research (Parent K24)"
REQUEST FOR APPLICATIONS

- **TITLE:** National Centers for Cryoelectron Microscopy (U24)  
  **SPONSOR:** NIH Roadmap Initiatives  
  **Synopsis:** This NIH Common Fund initiative will establish national service centers to increase research capacity for molecular structure determination by high resolution cryoelectron microscopy (cryoEM). The centers will address Common Fund infrastructure and workforce goals for cryoEM by providing access to state-of-the-art equipment, technical support, and cross-training for the production and analysis of high-resolution data. The centers will offer equal-opportunity nationwide access to services through an open application process.  
  Application Receipt Date(s): June 30, 2017

- **TITLE:** NIH-DoD-VA Pain Management Collaboratory - Pragmatic Clinical Trials Demonstration Projects (UG3/UH3)  
  **SPONSOR:** National Center for Complementary and Integrative Health, National Institute on Alcohol Abuse and Alcoholism  
  **Synopsis:** Awards made under this FOA will initially support a two-year milestone-driven planning phase (UG3), with possible transition to a pragmatic trial Demonstration Project implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative, jointly supported by the NIH, DoD, and VA, is to develop the capacity to implement cost-effective large-scale clinical research in military and veteran health care delivery organizations focusing on non-pharmacological approaches to pain management and other comorbid conditions. The NIH, DoD, and VA expect to: establish a Coordinating Center that will provide national leadership and technical expertise for all aspects of health care system (HCS) focused research including assistance to UG3/UH3 grant applicants. Primary outcomes of treatment interventions include assessing pain and pain reduction, ability to function in daily life, quality of life, and medication usage/reduction/discontinuation. Secondary outcomes focusing on assessing comorbid conditions or those co-occurring with high frequency in this population are also of interest under the FOA.  
  Application Receipt Date(s): March 3, 2017

- **TITLE:** NIH-DoD-VA Pain Management Collaboratory - Coordinating Center (U24)  
  **SPONSOR:** National Center for Complementary and Integrative Health, National Institute on Drug Abuse, Office of Research on Women's Health
Synopsis: The purpose of this FOA is to solicit applications for a Coordinating Center (CC) to provide national leadership for the NIH-DoD-VA Health Care Systems (HCS) Research Collaboratory program on non-pharmacological approaches to pain management and comorbidities in U.S. military personnel, veterans and their families. For brevity, this initiative will be referred to as the “NIH-DoD-VA Pain Management Collaboratory.” Coordinating Center applicants will need to: 1) develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research in partnership with health care systems focused on military personnel, veterans, and their families; 2) work collaboratively with and provide technical, design, and other support to Demonstration Project teams, to develop and implement a pragmatic trial protocol; and 3) disseminate widely Collaboratory-endorsed policies and best practices and lessons learned in the Demonstration Projects for implementing research within health care settings. Application Receipt Date(s): March 3, 2017

**TITLE:** Canine Immunotherapy Trials and Correlative Studies (U01)  
**(RFA-CA-17-001)**  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This Funding Opportunity Announcement (FOA) will support canine clinical studies using immunotherapeutic agents and novel drug combinations (such as immune modulators, molecular targeted agents, chemotherapy, and/or radiation) together with laboratory correlative studies that seek to describe characterize and understand the cellular and molecular mechanisms that determine the anti-tumor response (or non-response) in dogs with spontaneous tumors. The FOA will support a network of laboratories and canine clinical trial sites. A companion funding opportunity (see U24 funding opportunity RFA-CA-17-002) will support a coordinating center that will aid in the development, standardization, and conduct of the clinical and laboratory studies as well as data management across the funded U01 sites. Application Receipt Date(s): March 7, 2017

**TITLE:** Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)  
**(RFA-CA-17-002)**  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This Funding Opportunity Announcement (FOA) will support a coordinating center for a network of cooperative agreements (see U01 FOA RFA-CA-17-001) that will conduct clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials. This FOA will work with the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component and will provide statistical support; assist with the development and standardization of clinical protocols and laboratory immune monitoring assays; assist with the implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; manage clinical and correlative data from all U01 sites and their collaborators including immune-related adverse events; facilitate the sharing of agents, specimens, and data; and create an ad hoc steering committee of required expertise--both inside and outside the U01 network, including the PD/Pi's of the U01s, representatives of the COP and the NCI Program Official--to ensure that the goals of the network are accomplished. Application Receipt Date(s): March 7, 2017

**TITLE:** Cancer Immune Monitoring and Analysis Centers (U24)  
**(RFA-CA-17-005)**  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This (FOA) solicits applications for multidisciplinary Cancer Immune Monitoring and Analysis Centers (CIMACs) that will serve as the main units of the Network for correlative studies in clinical trials involving immunotherapy. The Network will encompass two to three CIMACs (to be supported by this FOA) and a single Cancer Immunologic Data Commons (CIDC) (to be supported by the companion FOA, (RFA-CA-17-006) forming a CIMACs-CIDC Network. The Network is established to address the critical importance of biomarkers in management of cancer patients receiving immunotherapy. Specifically, each CIMAC will encompass a multidisciplinary group with basic, translational, clinical, and computational research expertise. CIMACs are expected to provide a wide range of state-of-the-art analyses for genomic, phenotypic and functional characterization of responses of patients in the NCI-sponsored early phase clinical trials using analytically-validated and standardized platforms. The Network activities will be facilitated by the CIDC in the following main areas: optimization of data collection methodologies suitable for immune-related biomarkers, data integration and building a biomarker database for the secondary use by the large immunology community. The long term goal of the CIMACs-CIDC Network is to develop molecular signatures that define immune response categories to correlate with the clinical outcomes of immunotherapy in cancer. Collectively, the outcome of the Network research should lead to the identification of biomarkers with a translational potential for optimizing the therapeutic strategies for patients. Application Receipt Date(s): March 3, 2017

**TITLE:** Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)  
**(RFA-CA-17-015)**  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to stimulate research in the area of PDAC microenvironment with the ultimate goal of understanding the interaction between tumors and the microenvironment. The plan is to design new immunotherapy and combination interventions that would accommodate and build on the
distinct characteristics of this interaction. It is expected that the interventions will lead to improved responses in pre-
clinical models and clinical evaluation either in NCI-based early phase networks (ETCTN), or by industry or cancer
centers.
Application Receipt Date(s): March 7, 2017

- **TITLE:** Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This funding opportunity announcement (FOA) invites applications to establish a Resource Center (RC) for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (Consortium) that has the ultimate goal to design new immunotherapy and combination interventions in PDAC. The RC will support the administrative coordination of the Consortium, create and support database(s) for data pertinent to the Consortium. It will secure centralized tissue banking for specimens submitted by the members of the Consortium and a virtual biospecimen database that would include all tissue resources of the Consortium. The RC will provide centralized bioinformatics and data analysis support, establish in vivo and in vitro model repositories and distribution units. Lastly, the RC will support meeting and communications coordination among members of Consortium, and form and maintain a Consortium website.
  Application Receipt Date(s): March 7, 2017.

- **TITLE:** NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35)
  **SPONSOR:** National Institute of Dental and Craniofacial Research
  **Synopsis:** The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
  Application Receipt Date(s): March 30, 2017

- **TITLE:** Therapeutic Targeting Of The Human Islet Environment (UC4)
  **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases
  **Synopsis:** This Funding Opportunity Announcement (FOA) solicits applications for projects to develop strategies to target the human pancreatic environment in-vivo to deliver cell-based therapeutics, regulatory molecules or gene constructs that can protect or replenish the functional beta cell mass, or to develop synthetic sentinel biomarkers to safely monitor beta cell stress or disease initiation prior to the appearance of autoantibodies in individuals at risk of developing Type 1 Diabetes (T1D). Successful applicants will join the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase functional human beta cell mass in vivo through the controlled manipulation of beta cell replication, islet cell plasticity, or the reprogramming of pancreatic non-beta cells into beta-like cells. CTAR is part of the Human Islet Research Network (HIRN).
  Application Receipt Date(s): March 22, 2017.

- **TITLE:** Competitive Collaborative Projects for Human Islet Biology (UC4)
  **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases
  **Synopsis:** This Funding Opportunity Announcement solicits applications for collaborative research projects that will enhance the goals of the Human Islet Research Network (HIRN; www.hirnetwork.org). The HIRN is a collaborative program consisting of multiple related but distinct research consortia focused around two common goals: increasing our understanding of how human beta cells are lost in Type 1 Diabetes (T1D), and finding innovative strategies to protect or replace functional beta cell mass in diabetic patients. Applicants to this FOA will be expected to lend unique perspectives and novel approaches to the network, and will be expected to pursue experiments that will be consistent with HIRN's continuing emphasis on studies that elucidate key aspects of human biology and physiology.
  Application Receipt Date(s): March 23, 2017

- **TITLE:** Integrative Research in Gynecologic Health (R01)
  **SPONSOR:** Eunice Kennedy Shriver National Institute of Child Health and Human Development
  **Synopsis:** The purpose of this FOA is to encourage integrated and synergistic research in the study of uterine fibroids, endometriosis, adenomyosis, or gynecologic pain syndromes.
  Application Receipt Date(s): March 31, 2017

- **TITLE:** Innovations for Healthy Living - Improving Population Health and Eliminating Health Disparities (R43/R44)
  **SPONSOR:** National Institute on Minority Health and Health Disparities
**Synopsis:** This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes and in preventing disease and improving health in one or more NIH-defined health disparity population group(s). Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

Application Receipt Date(s): February 22, 2017

**TITLE:** Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42)  
**SPONSOR:** National Institute on Minority Health and Health Disparities  

**Synopsis:** This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes in one or more NIH-defined health disparity population group(s). Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

Application Receipt Date(s): February 22, 2017

**TITLE:** Novel Analytical Approaches for Metabolomics Data (R03)  
**SPONSOR:** NIH Roadmap Initiatives  

**Synopsis:** The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between computational scientists, metabolomics experts, and biomedical researchers in developing, piloting, and/or validating novel bioinformatic approaches that address current analytical hurdles in metabolomics data. A goal of providing powerful approaches that will be useful to biomedical researchers, as well as bioinformaticians, is particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide a tool for broader use by the biomedical research community. Projects are expected to use existing, publicly available metabolomics data and complement the efforts and resources of the Common Fund Metabolomics Program.

Application Receipt Date(s): February 14, 2017

**PROGRAM ANNOUNCEMENTS**

**TITLE:** Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)  
**SPONSOR:** National Cancer Institute  

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. The scientific scope of this FOA includes: Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support; Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials. A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development and optimization of QI tools and methods chosen for study by the investigating team, while the UH3 phase is for the validation of the tools/methods developed in the UG3 phase. The UG3 phase can be no more than 2 years in duration, and the total project cannot exceed 5 years. At completion, UG3 projects will be reviewed by program staff. Those that have met their milestones may be administratively considered by NCI program staff for transition to the UH3 validation phase.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)  
**SPONSOR:** National Cancer Institute  

**Synopsis:** This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.

Application Receipt/Submission Date(s): Multiple dates, see announcement
• **TITLE:** Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01)
  **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases
  **Synopsis:** This FOA will provide support for assays (and associated data analysis) of repository-held samples for studies focused on an NIDDK relevant disease. The review of applications to this FOA will consider both access to repository-held samples and funding for assays using the samples. These studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, disease progression, or clinical responses. Projects that make good use of the associated data from the clinical trials and studies, the original intent of the clinical study and/or trial are highly encouraged. Exploratory studies and discovery research are encouraged especially when samples are not severely limited, the work is justified, and the goal is consistent with the original intent of the clinical research.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Perception and Cognition Research to Inform Cancer Image Interpretation (R01) (R21)
  **SPONSOR:** National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Targeted basic behavioral and social science and intervention development for HIV prevention and care (R21)
  **SPONSOR:** National Institute of Mental Health
  **Synopsis:** This FOA encourages research designed to (a) conduct basic behavioral and social science research that is needed to advance the development of HIV prevention and care interventions, (b) translate and operationalize the findings from these basic studies to develop interventions and assess their acceptability and feasibility and (c) conduct tests of the efficacy of HIV prevention and care interventions. **PA-17-106** uses the R01 grant mechanism while this FOA uses the R21 mechanism.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** NK Cells to Induce Immunological Memory to Prevent HIV Infection (R01)
  **SPONSOR:** National Institute of Allergy and Infectious Diseases
  **Synopsis:** This FOA encourages research designed to (a) conduct basic behavioral and social science research that is needed to advance the development of HIV prevention and care interventions, (b) translate and operationalize the findings from these basic studies to develop interventions and assess their acceptability and feasibility and (c) conduct tests of the efficacy of HIV prevention and care interventions. **PA-17-106** uses the R01 grant mechanism while this FOA uses the R21 mechanism.
  Application Receipt/Submission Date(s): Multiple dates, see announcement
Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate and support investigator-driven collaborative research to: 1) probe how vaccine-elicited antibodies protect against viral acquisition via Fc receptor (FCR)-mediated mechanisms; and 2) determine the functional profiles of Fc receptor engagement in the context of immune responses elicited by protective vaccines, to inform advancement of similarly promising HIV vaccine candidates.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Chronic Condition Self-Management in Children and Adolescents (R01)  
  **SPONSOR:** National Institute of Nursing Research  
  **Synopsis:** Managing a chronic condition is an unremitting responsibility for children and their families. Children with a chronic condition and their families have a long-term responsibility for self-management. This FOA encourages research that takes into consideration various factors that influence self-management such as individual differences, biological and psychological factors, family/caregivers and sociocultural context, family-community dynamics, healthcare system factors, technological advances, and the role of the environment.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Chronic Condition Self-Management in Children and Adolescents (R21)  
  **SPONSOR:** National Institute of Nursing Research  
  **Synopsis:** This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non-traditional settings.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Reducing Health Disparities Among Minority and Underserved Children (R21)  
  **SPONSOR:** National Institute of Nursing Research, National Institute on Deafness and Other Communication Disorders  
  **Synopsis:** This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non-traditional settings.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Reducing Health Disparities Among Minority and Underserved Children (R01)  
  **SPONSOR:** National Institute of Nursing Research, National Institute on Deafness and Other Communication Disorders  
  **Synopsis:** This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non-traditional settings.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)  
  **SPONSOR:** National Institute on Drug Abuse  
  **Synopsis:** This FOA encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment.

Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** NINDS Exploratory Clinical Trials (R01)  
  **SPONSOR:** National Institute of Neurological Disorders and Stroke  
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for
investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

**Application Receipt/Submission Date(s):** March 21, 2017

- **TITLE:** Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations An ORWH FY17 Administrative Supplement (Admin Supp)
  (PA-17-101)
**SPONSOR:** Office of Research on Women's Health, National Center for Advancing Translational Sciences, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, Office of Behavioral and Social Science Research, Office of Disease Prevention

**Synopsis:** The Office of Research on Women’s Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences at the intersection of race/ethnicity and other social determinants in human health and illness, including preclinical, clinical and behavioral studies. The purpose of this FOA is to provide Administrative Supplements to active NIH parent grants for one year to address health disparities among women of populations in the US who are underrepresented, understudied and/or underreported in biomedical research. The proposed research must address an area within Objective 3.9 (Goal 3.0) of the NIH Strategic Plan for Research on Women’s Health which states: “Examine health disparities among women stemming from differences in such factors as race and ethnicity, socioeconomic status, gender identity, and urban-rural living, as they influence health, health behaviors, and access to screening and therapeutic interventions.”

**Application Receipt/Submission Date(s):** March 21, 2017

- **TITLE:** NINDS Efficacy Clinical Trials (U01)
  (PAR-17-102)
**SPONSOR:** National Institute of Neurological Disorders and Stroke

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

**Application Receipt/Submission Date(s):** March 21, 2017

- **TITLE:** Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01)
  (PA-17-060)
**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

**Application Receipt/Submission Date(s):** Multiple dates, see announcement

- **TITLE:** Utilizing Health Information Technology to Scale and Spread Successful Practice Models Using Patient-reported Outcomes (R18)
  (PA-17-077)
**SPONSOR:** Agency for Healthcare Research and Quality

**Synopsis:** This Funding Opportunity Announcement (FOA) invites R18 grant applications for research that demonstrates how health information technology (IT) can improve patient-centered health outcomes and quality of care in primary care and other ambulatory settings through the scale and spread of successful, health IT-enabled practice models that use patient-reported outcome (PRO) measures to achieve these objectives.

**Application Receipt/Submission Date(s):** Multiple dates, see announcement
• **TITLE:** Administrative Supplement for Research on Sex/Gender Influences (Admin Supp) (PA-17-078)

**SPONSOR:** Office of Research on Women's Health, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institute on Drug Abuse National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research National Library of Medicine, Office of Disease Prevention, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Synopsis:** The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences and/or sex and gender factors in human health and illness, including basic, preclinical, clinical and behavioral studies. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.

**Application Receipt/Submission Date(s):** February 13, 2017

• **TITLE:** Secondary Analyses of Existing Cohorts, Data Sets and Stored Biospecimens to Address Clinical Aging Research Questions (R01) (R21) (PA-17-088) (PA-17-089)

**SPONSOR:** National Institute on Aging

**Synopsis:** This funding opportunity announcement (FOA) invites applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on aging changes influencing health across the lifespan, and/or on diseases and disabilities in older persons.

**Application Receipt/Submission Date(s):** Multiple dates, see announcement

• **TITLE:** NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp) (PA-17-090)

**SPONSOR:** National Library of Medicine, National Cancer Institute, National Human Genome Research Institute National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders National Institute of General Medical Sciences, National Institute of Nursing Research, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Synopsis:** The National Library of Medicine, in conjunction with NIH Institutes and Centers (ICs) named above, announces an Administrative Supplement opportunity available to eligible NIH awardees with active R01 grants and, in some cases, with the other active awards with the activity codes listed above. (see IC-specific details in the Activity Code section above). These administrative supplements provide funds to active awards of participating Institutes and Centers in order to enhance the storage, organization, management and use of digital research data through the involvement of informationists, also known as in-context information specialists. The purposes of this administrative supplement program are (1) to enhance collaborative, multi-disciplinary basic and clinical research by integrating an information specialist into the research team in order to improve the capture, storage, organization, management, integration, presentation and dissemination of digital biomedical research data; and (2) to assess the impact of the informationist’s participation.

**Application Receipt/Submission Date(s):** March 15, 2017

• **TITLE:** Shared Instrumentation Grant (SIG) Program (S10) (PAR-17-074)

**SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Synopsis:** The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least $50,000. There is no maximum price requirement; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass and nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.

**Application Receipt/Submission Date(s):** May 31, 2017

• **TITLE:** Shared Instrumentation for Animal Research (SIFAR) Grant Program (S10) (PAR-17-075)

**SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Programs

**Synopsis:** The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. This Funding Opportunity Announcement (FOA) supports requests for state-of-the-art commercially available technologies needed for NIH-funded research using vertebrate and invertebrate animal species. It is expected that the use of the awarded instruments will enhance the scientific rigor of animal research and improve the reproducibility of experimental outcomes. One item of the requested instrumentation must cost at least $50,000. No instrument in a cluster can cost less than $20,000. There is no maximum price requirement; however, the maximum award is $750,000.

Application Receipt/Submission Date(s): May 31, 2017

- **TITLE:** High-End Instrumentation (HEI) Grant Program (S10)  
  (PAR-17-076)  
  **SPONSOR:** Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
  **Synopsis:** The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least $600,001. The maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffraction systems, nuclear magnetic resonance (NMR) and mass spectrometers, DNA and protein sequencers, biosensors, electron and confocal microscopes, cell-sorters, and biomedical imagers.
  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** NIBIB Biomedical Technology Resource Centers (P41)  
  (PAR-17-083)  
  **SPONSOR:** National Institute of Biomedical Imaging and Bioengineering  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.
  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Tobacco Use and HIV in Low and Middle Income Countries (R01)  
  (PAR-17-087)  
  **SPONSOR:** National Cancer Institute, National Institute on Drug Abuse  
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Fertility Status as a Marker for Overall Health (R01) (R21)  
  (PA-17-091)  
  **SPONSOR:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program.
  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

- **TITLE:** Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)  
  (PA-17-098)  
  **SPONSOR:** National Institutes of Health, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Cancer Institute, National Human Genome Research Institute National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Nursing Research, Office of AIDS Research, Office of Disease Prevention, Office of Research on Women's Health  
  **Synopsis:** The NIH Office of the Director announces the availability of administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. SGM populations include, but are not limited to, lesbian, gay, bisexual, and transgender people, and individuals with differences or disorders of sexual development
(sometimes referred to as “intersex” or as specific diagnoses). This trans-NIH effort, which involves multiple Institutes, Centers and Offices from across NIH, is intended to encourage investigation in this underrepresented, but growing, field of research.

Application Receipt/Submission Date(s): March 1, 2017

**TITLE:** Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)  
**(PAR-17-093)**

**SPONSOR:** National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases  

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Maximizing Investigators' Research Award (R35)  
**(PAR-17-094)**

**SPONSOR:** National Institute of General Medical Sciences  

**Synopsis:** The Maximizing Investigators’ Research Award (MIRA) is a grant to provide support for the program of research in an investigator's laboratory that falls within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30)  
**(PAR-17-095)**

**SPONSOR:** National Cancer Institute  

**Synopsis:** This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Jointly Sponsored Ruth L. Kirschstein National Research Service Award for Institutional Predoctoral Training Programs in the Neurosciences (T32)  
**(PAR-17-096)**

**SPONSOR:** National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse, National Institute of General Medical Sciences, National Institute of Mental Health  

**Synopsis:** The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Planning for Non-Communicable Diseases and Disorders Research Training Programs in Low and Middle Income Countries (D71)  
**(PAR-17-097)**

**SPONSOR:** John E. Fogarty International Center  

**Synopsis:** This Funding Opportunity Announcement (FOA) for research training program planning invites submissions from low- and middle-income country (LMIC) institution(s) with existing research and research training capacity in chronic, non-communicable diseases and disorders (NCDs). These institutions must propose to assess needs and develop a plan for a research training program within the LMIC(s) that will further strengthen the capacity of LMIC individuals, institution(s) and country(ies) to identify NCD priorities and conduct NCD research across the lifespan. The application from the LMIC institution(s) may include collaboration with United States (U.S) institutions and other LMIC institutions as justified and appropriate.

Application Receipt/Submission Date(s): Multiple dates, see announcement

**OTHER FUNDING OPPORTUNITIES**  
(Sponsors in bold are NIH Peer Reviewed Organizations)

**TITLE:** RFA: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families  

**SPONSOR:** American Cancer Society (ACS)
• TITLE: Cancer Research Grants
  http://www.pardeefoundation.org/grants.aspx
  SPONSOR: Elsa U. Pardee Foundation

• TITLE: Exceptional Project Grants
  http://breastcanceralliance.org/grants/
  SPONSOR: Breast Cancer Alliance (BCA)

• TITLE: Education and Outreach Grants
  http://breastcanceralliance.org/grants-2/
  SPONSOR: Breast Cancer Alliance (BCA)

• TITLE: Young Investigator Grants
  http://breastcanceralliance.org/grants
  SPONSOR: Breast Cancer Alliance (BCA)

• TITLE: Pancreatic Cancer Action Network - NCI, Frederick National Laboratory for Cancer Research KRAS Travel Scholarship
  https://www.pancan.org/research/grants-program/apply-for-a-pancreatic-cancer-research-grant/
  SPONSOR: Pancreatic Cancer Action Network (PANCAN)

• TITLE: Irvington Postdoctoral Fellowships
  http://www.cancerresearch.org/postdoc/apply
  SPONSOR: Cancer Research Institute (CRI)

• TITLE: Pancreatic Cancer Action Network Precision Medicine Targeted Grant
  https://www.pancan.org/research/grants-program/apply-for-a-pancreatic-cancer-research-grant/
  SPONSOR: Pancreatic Cancer Action Network (PANCAN)

• TITLE: Damon Runyon-Sohn Pediatric Cancer Fellowship Award
  https://www.damonrunyon.org/for-scientists/application-guidelines/sohn
  SPONSOR: Damon Runyon Cancer Research Foundation

• TITLE: Early Detection Targeted Grant
  https://www.pancan.org/research/grants-program/apply-for-a-pancreatic-cancer-research-grant/
  SPONSOR: Pancreatic Cancer Action Network (PANCAN)

• TITLE: ASPIRE Oncology/Hematology Research Awards Program
  http://www.aspireresearch.org/onc/index.html
  SPONSOR: Pfizer, Inc., Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE Research Awards)

• TITLE: ATA Research Grants
  http://www.thyroid.org/professionals/research-grants/
  SPONSOR: American Thyroid Association (ATA)

• TITLE: Research Fellow Award Program
  https://www.themmrf.org/research-partners/mmrf-learning-network/research-grants/
  SPONSOR: Multiple Myeloma Research Foundation (MMRF)

• TITLE: National Capital Region Community Grants
  http://ww5.komen.org/WhatWeDo/InTheCommunity/NationalCommunityHealthPrograms/NationalCommunityHealthPrograms.html
  SPONSOR: Susan G. Komen for the Cure

• TITLE: Roentgen Resident/Fellow Research Award
  https://www.rsna.org/Roentgen_Research_Award.aspx
  SPONSOR: Radiological Society of North America (RSNA), RSNA Research & Education (R&E) Foundation

• TITLE: Postdoctoral Fellowships
  http://www.inrs.ca/english/graduate-studies/postdoctoral-fellowship
SPONSOR: National Institute of Scientific Research (INRS)

- TITLE: Summer Science-Writing Internship  
  http://www.anl.gov/news-room/summer-science-writing-internship  
  SPONSOR: United States Department of Energy (DOE), Argonne National Laboratory (ANL)

- TITLE: Grant Program  
  http://www.jgbf.org/  
  SPONSOR: James Graham Brown Foundation, Inc.

- TITLE: Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21]  
  SPONSOR: United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)

- TITLE: PCORI Funding Announcement: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes  
  http://www.pcori.org/funding-opportunities/announcement/pragmatic-clinical-studies-evaluate-patient-centered-outcomes-1  
  SPONSOR: Patient-Centered Outcomes Research Institute (PCORI)

- TITLE: AALAS Grants for Laboratory Animal Science (GLAS) Program  
  https://www.aalas.org/elas#  
  SPONSOR: American Association for Laboratory Animal Science (AALAS)

- TITLE: Behavioral Integrative and Treatment Development Program (R01)  
  SPONSOR: United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)

- TITLE: PCORI Funding Announcement: Addressing Disparities  
  http://www.pcori.org/funding-opportunities/announcement/addressing-disparities-cycle-1-2017  
  SPONSOR: Patient-Centered Outcomes Research Institute (PCORI)

- TITLE: Bladder Cancer Research Innovation Award  
  http://www.bcan.org/research/grants/bladder-cancer-research-innovation-award/  
  SPONSOR: Bladder Cancer Advocacy Network (BCAN)

- TITLE: Broad Agency Announcement (BAA) for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures for BARDA  
  https://www.fbo.gov/index?s=opportunity&mode=form&id=e7fad0d9693597168cf5bb7e498eb138&tab=core&_cview=1  
  SPONSOR: United States Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response

- TITLE: Prostate Cancer Foundation Young Investigator Awards  
  SPONSOR: Prostate Cancer Foundation (PCF)

- TITLE: Research Grants for Independent Investigators: Institutional Research Grants  
  http://www.cancer.org/research/applyforaresearchgrant/granttypes/institutional-research-grants  
  SPONSOR: American Cancer Society (ACS)

- TITLE: Grants  
  http://fdnweb.org/kornfeld/application-procedures/  
  SPONSOR: Kornfeld Foundation, Emily Davie and Joseph S.